Late-onset neutropenia (LON) after low-dose rituximab treatment in living related kidney transplantation - Single-center study

Transplant Immunology

Volumn 28, Issue 2-3, 2013, Pages 93-99

  Ishida, Hideki ^a   Inui, Masashi ^a   Furusawa, Miyuki ^a   Tanabe, Kazunari ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

BAFF; Late onset neutropenia; Renal transplantation; Rituximab

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; LYMPHOTOXIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD GROUP ABO INCOMPATIBILITY; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; FEMALE; HLA TYPING; HOMEOSTASIS; HUMAN; HUMAN TISSUE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LATE ONSET NEUTROPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 84879794288     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2013.01.003     Document Type: Article

References (20)

1. De La Torre I, Leandro MJ, Valor L, et al. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab; relationship with b-cell kinetics. Rheumatology 2012;51(5):833-40.
2. Malnick S, Duek G, Melzer E, Basevitz A. The treatment of autoimmune hepatitis. Curr Clin Pharmacol Jul 9 2012;7(4):318-27.
3. Cooper N, Stasi R, Cunningham-Rundles S, et al. Platelets-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia. Br J Haematol 2012;158(4):539-47.
4. Gregersen JW, Jayne DR. B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol 2012;8(9):505-14.
5. Fehr T, Stussi G. ABO-incompatible kidney transplantation. Curr Opin Organ Transplant 2012;17(4):376-85.
6. Tzvetanov I, Spaggiari M, Oberholzer J, et al. Cell population in spleens during antibody mediated rejection pathologic and clinical findings. Transplantation 2012;94(3):255-62.
7. Rozman S, Sonc M, Novakovic BJ. Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy. Leuk Lymphoma May 12 2012;53(10):1945-8.
8. Wolach O, Shpilberg O, Lahav M. Neutropenia after rituximab treatment: new insights on a late complication. Curr Opin Hematol 2012;19(1):32-8.
9. Tesfa D, Palmblad J. Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expert Rev Hematol 2011;4(6):619-25.
10. Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 2010;89(5):308-18.
11. Toki D, Ishida H, Horita S, et al. Impact of low-dose rituximab on splenic B cells in ABO incompatible renal transplant recipients. Transpl Int 2009;22(4):447-54.
12. Kohei N, Hirai T, Omoto K, Ishida H, Tanabe K. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012;12(2):469-76.
13. Zarkhin S, Lovelace PA, Li L, Hsieh SC, Sarwal MM. Phenotypic evaluation of B-cell subsets after rituximab for treatment of acute renal allograft rejection in pediatric recipients. Transplantation 2012;91(9):1010-8.
14. El Eter EA, Aldrees A. Inhibition of proinflammatory cytokines by SCH79797, a selective protease-activated receptor 1 antagonist, protects rat kidney against ischemia-reperfusion injury. Shock 2012;37(6):639-44.
15. Zafrani L, Truffaut L, Kreis H, et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation; a retrospective study. Am J Transplant 2009;9(8):1816-25.
16. Ronald FP, Kumar V, Robert RR, et al. B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation. Transplant Rev 2010;24:207-21.
17. Terrier B, Ittah M, Tourneur L, et al. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica 2007;92(2):e20-3.
18. Clatworthy MR, Watson C, Plotnek G, et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009;360(25):2683-5.
19. Thibaut-Espitia A, Foucher Y, Danger R, et al. BAFF and BAFF-R levels are associated with risk of long-term kidney graft dysfunction and development of donor specific antibodies. Am J Transplant 2012;12(10):2754-62.
20. Li SC, Chen YC, Evens AM, et al. Rituximab induced late onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism. Am J Hematol 2010;85(10):810-2.